Second-line Treatment of Metastatic Colorectal Cancer

This study is testing a second-line treatment approach for metastatic colorectal cancer — cancer of the colon or rectum that has spread to other organs — in patients whose cancer has progressed after initial (first-line) chemotherapy. The trial evaluates a treatment combination to see whether it can slow or reverse disease progression. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed metastatic or recurrent colorectal cancer (adenocarcinoma) - Your cancer progressed during or after first-line treatment that included 5-FU or capecitabine, oxaliplatin, and a targeted therapy (bevacizumab or cetuximab) - You have at least one measurable tumor on scans - Your general health status is good (ECOG 0–1) and your life expectancy is more than 3 months - Your blood counts, kidney, and liver function meet the required levels **You may NOT be eligible if...** - You have not received prior first-line chemotherapy - Your organ function does not meet the required levels - You are pregnant or not using adequate contraception - Your urine protein levels are too high Talk to your doctor to see if this trial is right for you.